Gastroenterology, First Affiliated Hospital. China Medical University, china.
Gastroenterology, First Affiliated Hospital. China Medical University.
Rev Esp Enferm Dig. 2022 Dec;114(12):757-758. doi: 10.17235/reed.2022.8964/2022.
It is difficult to manage UC patients with tumor and extraintestinal manifestations (EIMs). We present this case of acute severe UC patient with peripheral arthritis and orbital tumor could be successfully managed by the concomitant use of two biologics (Dual targeted therapy, DTT) including vedolizumab (VDZ) and ustekinumab (UST). VDZ is approved for the treatment of patients with moderate-to-severe UC, but might have limited efficacy in treating EIMs due to its gut specific mechanism. UST shows clinical efficacy in the treatment of EIMs and is used for UC treatment.
对于伴有肿瘤和肠外表现（EIMs）的 UC 患者，其管理具有一定难度。我们现报告一例伴有外周关节炎和眼眶肿瘤的急性重度 UC 患者，该患者通过同时使用两种生物制剂（vedolizumab [VDZ] 和 ustekinumab [UST]，即双重靶向治疗，DTT）成功治疗。VDZ 获批用于治疗中重度 UC 患者，但由于其肠道特异性作用机制，在治疗 EIMs 方面可能疗效有限。UST 在治疗 EIMs 方面具有临床疗效，且可用于 UC 治疗。
